Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience

Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience

(2016) Whitney E. Jackson et al.   CLINICAL TRANSPLANTATION

Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study

(2016) Elliot B. Tapper et al.   HEPATOLOGY

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

(2016) Michael Manns et al.   LANCET INFECTIOUS DISEASES

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation

(2016) Neil E. Crittenden et al.   LIVER TRANSPLANTATION

Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients

(2016) Yoshihide Ueda et al.   TRANSPLANTATION

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

(2015) Michael Charlton et al.   GASTROENTEROLOGY

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant

(2015) Surakit Pungpapong et al.   HEPATOLOGY

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

(2015)   HEPATOLOGY

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

(2015) Masashi Mizokami et al.   LANCET INFECTIOUS DISEASES

Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

(2015) Sammy Saab et al.   LIVER INTERNATIONAL

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

(2015) Julio A. Gutierrez et al.   LIVER TRANSPLANTATION

Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network

(2015) Robert S. Brown et al.   LIVER TRANSPLANTATION

Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation

(2015) Yoshihide Ueda et al.   TRANSPLANT INTERNATIONAL

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

(2014) Hiromitsu Kumada et al.   HEPATOLOGY

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liver transplantation in the setting of chronic HCV

(2012) Norah Terrault   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment

(2012) Marina Berenguer et al.   JOURNAL OF HEPATOLOGY